Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Logunov DY, et al. Among authors: zubkova ov. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis.
Burmistrova DA, Tillib SV, Shcheblyakov DV, Dolzhikova IV, Shcherbinin DN, Zubkova OV, Ivanova TI, Tukhvatulin AI, Shmarov MM, Logunov DY, Naroditsky BS, Gintsburg AL. Burmistrova DA, et al. Among authors: zubkova ov. PLoS One. 2016 Mar 10;11(3):e0150958. doi: 10.1371/journal.pone.0150958. eCollection 2016. PLoS One. 2016. PMID: 26962869 Free PMC article.
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel'skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL. Dolzhikova IV, et al. Among authors: zubkova ov. Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620. doi: 10.1080/21645515.2016.1238535. Epub 2017 Feb 2. Hum Vaccin Immunother. 2017. PMID: 28152326 Free PMC article. Clinical Trial.
Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.
Ozharovskaia TA, Zubkova OV, Dolzhikova IV, Gromova AS, Grousova DM, Tukhvatulin AI, Popova O, Shcheblyakov DV, Scherbinin DN, Dzharullaeva AS, Erokhova AS, Shmarov MM, Loginova SY, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Ozharovskaia TA, et al. Among authors: zubkova ov. Acta Naturae. 2019 Jan-Mar;11(1):38-47. Acta Naturae. 2019. PMID: 31024747 Free PMC article.
Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.
Shcheblyakov D, Esmagambetov I, Simakin P, Kostina L, Kozlov A, Tsibezov V, Grebennikova T, Chifanov D, Rumyantseva I, Boyarskaya N, Sizikova T, Shagarova N, Andrus А, Shatohina I, Syromyatnikova S, Kovalchuk A, Pantyukhov V, Borisevich S, Zubkova O, Tukhvatulin A, Logunov D, Naroditsky B, Gintsburg A. Shcheblyakov D, et al. Antiviral Res. 2019 Dec;172:104617. doi: 10.1016/j.antiviral.2019.104617. Epub 2019 Oct 5. Antiviral Res. 2019. PMID: 31593751
Gene-modified leucoconcentrate for personalized ex vivo gene therapy in a mini pig model of moderate spinal cord injury.
Islamov RR, Bashirov FV, Sokolov ME, Izmailov AA, Fadeev FO, Markosyan VA, Davleeva MA, Zubkova OV, Smarov MM, Logunov DY, Naroditskyi BS, Salafutdinov II, Rizvanov AA, Turaev RG. Islamov RR, et al. Among authors: zubkova ov. Neural Regen Res. 2021 Feb;16(2):357-361. doi: 10.4103/1673-5374.290902. Neural Regen Res. 2021. PMID: 32859798 Free PMC article.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Logunov DY, et al. Among authors: zubkova ov. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Lancet. 2020. PMID: 32896291 Free PMC article. Clinical Trial.
47 results